Share Price and Basic Stock Data
Last Updated: February 1, 2026, 8:43 pm
| PEG Ratio | -25.62 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gland Pharma Ltd, a prominent player in the Indian pharmaceuticals sector, reported a current share price of ₹1,692 and a market capitalization of ₹27,873 Cr. The company has demonstrated a steady revenue trajectory, with sales recorded at ₹4,401 Cr in FY 2022, followed by a slight decline to ₹3,617 Cr in FY 2023. However, projections for FY 2024 and FY 2025 indicate a recovery, with revenues expected to rise to ₹4,167 Cr and ₹4,116 Cr, respectively, reflecting a resilient demand for its pharmaceutical products. Quarterly sales figures have shown variability, with the latest reported sales of ₹1,011 Cr in September 2023, up from ₹884 Cr in June 2023. This trend underscores Gland Pharma’s capability to navigate market fluctuations effectively. The company’s operating profit margin (OPM) stood at 35%, indicating robust operational efficiency compared to industry standards, which typically range between 20-30% for pharmaceutical companies. Gland Pharma’s commitment to maintaining a strong revenue base positions it favorably within the competitive landscape.
Profitability and Efficiency Metrics
Gland Pharma’s profitability metrics demonstrate commendable performance, with a net profit of ₹1,156 Cr, translating to a net profit margin of 12.43% in FY 2025. The company’s return on equity (ROE) was reported at 11.6%, while the return on capital employed (ROCE) stood at 15.8%, both of which are solid indicators of efficient capital utilization. The operating profit for the latest quarter was ₹347 Cr, with an OPM of 34%, reflecting a significant recovery from the previous quarter’s performance of ₹259 Cr and 29%. The interest coverage ratio (ICR) of 35.30x highlights the company’s strong ability to meet its interest obligations, significantly exceeding the typical industry benchmark of 5-10x. This indicates a strong liquidity position and financial stability, reducing the risk of default. However, the fluctuating net profit figures across quarters, notably a dip to ₹79 Cr in March 2023, highlight potential vulnerabilities in maintaining consistent profitability amidst market challenges.
Balance Sheet Strength and Financial Ratios
Gland Pharma’s balance sheet reflects a robust financial position, characterized by total assets of ₹10,422 Cr and minimal borrowings of just ₹4 Cr. This translates to a total debt to equity ratio of 0.02, indicating an exceptionally low reliance on debt financing compared to industry norms, which can range from 0.5 to 1.5. The company’s reserves increased to ₹10,034 Cr, showcasing its ability to retain earnings and reinvest in growth. The cash conversion cycle (CCC) stood at 284 days, which is relatively high compared to the sector average, indicating potential inefficiencies in managing receivables and inventory. However, Gland Pharma’s current ratio of 4.33x and quick ratio of 3.26x demonstrate strong liquidity, providing a buffer against short-term liabilities. The price-to-book value (P/BV) ratio of 2.87x is indicative of market confidence in the company’s valuation, aligning with typical sector valuations. Overall, Gland Pharma’s balance sheet stability and strong liquidity position enhance its capacity for future investments and growth.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Gland Pharma reveals a diverse ownership structure, with promoters holding 51.83% of the equity, providing a controlling interest. Foreign institutional investors (FIIs) accounted for 7.90%, while domestic institutional investors (DIIs) held 32.63%, indicating substantial institutional support. This distribution suggests a balanced confidence among various stakeholders in the company’s growth trajectory. Notably, the number of shareholders has declined to 97,151 from a peak of 1,81,747 in June 2023, which may raise concerns regarding retail investor confidence. However, the steady increase in DII holdings from 23.13% in December 2022 to 32.63% in September 2025 reflects a growing institutional interest, which can provide stability and support for the stock. The gradual reduction in promoter shareholding from 57.86% to 51.83% over the same period raises questions about the long-term strategy and potential dilution of control. Nevertheless, the overall shareholding pattern indicates a solid foundation for investor confidence moving forward.
Outlook, Risks, and Final Insight
Gland Pharma’s outlook appears positive, supported by strong fundamentals, a robust balance sheet, and an improving profitability trend. However, the company faces risks, including the volatility in quarterly earnings, as seen in the fluctuations between ₹188 Cr and ₹321 Cr in net profit over recent quarters. Additionally, the high cash conversion cycle could hinder liquidity and operational efficiency if not addressed. The pharmaceutical industry remains competitive, and Gland Pharma must continue to innovate and adapt to changing market dynamics. Potential regulatory challenges and pricing pressures from generic competition could also impact future performance. Overall, Gland Pharma is well-positioned to capitalize on growth opportunities, provided it effectively manages its operational efficiency and maintains its strong financial health. Investors should monitor the company’s quarterly performance closely and remain cognizant of the broader economic landscape that could influence its operations.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 119 Cr. | 94.7 | 195/84.3 | 26.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,538 Cr. | 325 | 479/192 | 73.3 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.8 Cr. | 46.9 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 71.8 Cr. | 49.0 | 49.7/17.0 | 171 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,449.33 Cr | 1,087.86 | 46.53 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,048 | 926 | 785 | 884 | 1,011 | 1,098 | 1,175 | 1,012 | 1,063 | 1,011 | 1,030 | 1,039 | 1,074 |
| Expenses | 753 | 642 | 616 | 625 | 664 | 728 | 742 | 718 | 699 | 620 | 636 | 680 | 699 |
| Operating Profit | 295 | 284 | 169 | 259 | 347 | 369 | 433 | 294 | 364 | 391 | 394 | 359 | 375 |
| OPM % | 28% | 31% | 22% | 29% | 34% | 34% | 37% | 29% | 34% | 39% | 38% | 35% | 35% |
| Other Income | 66 | 62 | -18 | 35 | 41 | 43 | 47 | 48 | 58 | 65 | 44 | 55 | 83 |
| Interest | 2 | 3 | 2 | 2 | 1 | 1 | 5 | 1 | 0 | 18 | 3 | 7 | 4 |
| Depreciation | 37 | 38 | 38 | 39 | 40 | 40 | 43 | 41 | 42 | 44 | 43 | 44 | 45 |
| Profit before tax | 322 | 305 | 112 | 254 | 347 | 372 | 433 | 300 | 380 | 394 | 391 | 362 | 409 |
| Tax % | 26% | 25% | 29% | 26% | 26% | 26% | 26% | 26% | 26% | 25% | 26% | 26% | 26% |
| Net Profit | 240 | 228 | 79 | 188 | 258 | 277 | 321 | 223 | 282 | 295 | 290 | 269 | 302 |
| EPS in Rs | 14.55 | 13.82 | 4.81 | 11.39 | 15.64 | 16.81 | 19.51 | 13.53 | 17.10 | 17.91 | 17.60 | 16.34 | 18.33 |
Last Updated: January 1, 2026, 4:16 pm
Below is a detailed analysis of the quarterly data for Gland Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,074.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,039.00 Cr. (Jun 2025) to 1,074.00 Cr., marking an increase of 35.00 Cr..
- For Expenses, as of Sep 2025, the value is 699.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 680.00 Cr. (Jun 2025) to 699.00 Cr., marking an increase of 19.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 375.00 Cr.. The value appears strong and on an upward trend. It has increased from 359.00 Cr. (Jun 2025) to 375.00 Cr., marking an increase of 16.00 Cr..
- For OPM %, as of Sep 2025, the value is 35.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 35.00%.
- For Other Income, as of Sep 2025, the value is 83.00 Cr.. The value appears strong and on an upward trend. It has increased from 55.00 Cr. (Jun 2025) to 83.00 Cr., marking an increase of 28.00 Cr..
- For Interest, as of Sep 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 7.00 Cr. (Jun 2025) to 4.00 Cr., marking a decrease of 3.00 Cr..
- For Depreciation, as of Sep 2025, the value is 45.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 44.00 Cr. (Jun 2025) to 45.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 409.00 Cr.. The value appears strong and on an upward trend. It has increased from 362.00 Cr. (Jun 2025) to 409.00 Cr., marking an increase of 47.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 26.00%.
- For Net Profit, as of Sep 2025, the value is 302.00 Cr.. The value appears strong and on an upward trend. It has increased from 269.00 Cr. (Jun 2025) to 302.00 Cr., marking an increase of 33.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 18.33. The value appears strong and on an upward trend. It has increased from 16.34 (Jun 2025) to 18.33, marking an increase of 1.99.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:20 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 991 | 994 | 1,348 | 1,479 | 1,620 | 2,044 | 2,633 | 3,463 | 4,401 | 3,617 | 4,167 | 4,116 | 4,154 |
| Expenses | 630 | 678 | 845 | 854 | 1,085 | 1,338 | 1,678 | 2,161 | 2,890 | 2,598 | 2,758 | 2,674 | 2,635 |
| Operating Profit | 361 | 316 | 502 | 625 | 535 | 706 | 955 | 1,302 | 1,511 | 1,019 | 1,410 | 1,443 | 1,519 |
| OPM % | 36% | 32% | 37% | 42% | 33% | 35% | 36% | 38% | 34% | 28% | 34% | 35% | 37% |
| Other Income | 9 | 30 | 37 | 34 | 49 | 66 | 139 | 135 | 224 | 184 | 166 | 215 | 246 |
| Interest | 13 | 17 | 16 | 6 | 4 | 4 | 7 | 3 | 5 | 7 | 8 | 23 | 33 |
| Depreciation | 28 | 57 | 63 | 74 | 78 | 82 | 95 | 99 | 110 | 147 | 162 | 169 | 175 |
| Profit before tax | 327 | 272 | 459 | 578 | 502 | 686 | 993 | 1,335 | 1,619 | 1,048 | 1,405 | 1,466 | 1,557 |
| Tax % | 32% | 23% | 32% | 28% | 36% | 34% | 22% | 25% | 25% | 26% | 26% | 26% | |
| Net Profit | 224 | 209 | 314 | 414 | 321 | 452 | 773 | 997 | 1,212 | 776 | 1,043 | 1,090 | 1,156 |
| EPS in Rs | 190.40 | 133.53 | 202.40 | 267.01 | 207.24 | 291.65 | 49.88 | 60.94 | 73.78 | 47.11 | 63.34 | 66.14 | 70.18 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 32% | 27% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -6.70% | 50.24% | 31.85% | -22.46% | 40.81% | 71.02% | 28.98% | 21.56% | -35.97% | 34.41% | 4.51% |
| Change in YoY Net Profit Growth (%) | 0.00% | 56.94% | -18.39% | -54.31% | 63.27% | 30.21% | -42.04% | -7.41% | -57.54% | 70.38% | -29.90% |
Gland Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 9% |
| 3 Years: | -2% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 7% |
| 3 Years: | -3% |
| TTM: | 5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -8% |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 14% |
| 3 Years: | 12% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 4:45 am
Balance Sheet
Last Updated: December 4, 2025, 1:17 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 16 | 15 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 822 | 1,379 | 1,662 | 2,074 | 2,395 | 2,847 | 3,631 | 5,887 | 7,142 | 7,937 | 8,979 | 9,739 | 10,034 |
| Borrowings | 176 | 166 | 117 | 6 | 6 | 5 | 5 | 5 | 5 | 4 | 4 | 5 | 4 |
| Other Liabilities | 277 | 197 | 292 | 378 | 512 | 655 | 435 | 588 | 671 | 815 | 542 | 661 | 771 |
| Total Liabilities | 1,287 | 1,758 | 2,086 | 2,474 | 2,928 | 3,523 | 4,086 | 6,496 | 7,834 | 8,773 | 9,541 | 10,422 | 10,825 |
| Fixed Assets | 460 | 649 | 788 | 872 | 843 | 929 | 968 | 954 | 1,502 | 1,571 | 1,694 | 1,745 | 1,697 |
| CWIP | 208 | 192 | 202 | 161 | 199 | 123 | 188 | 338 | 191 | 177 | 120 | 42 | 53 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 163 | 8 | 2,386 | 2,790 | 3,293 |
| Other Assets | 619 | 917 | 1,096 | 1,441 | 1,887 | 2,471 | 2,929 | 5,203 | 5,978 | 7,017 | 5,342 | 5,845 | 5,783 |
| Total Assets | 1,287 | 1,758 | 2,086 | 2,474 | 2,928 | 3,523 | 4,086 | 6,496 | 7,834 | 8,773 | 9,541 | 10,422 | 10,825 |
Below is a detailed analysis of the balance sheet data for Gland Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
- For Reserves, as of Sep 2025, the value is 10,034.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,739.00 Cr. (Mar 2025) to 10,034.00 Cr., marking an increase of 295.00 Cr..
- For Borrowings, as of Sep 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 5.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 771.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 661.00 Cr. (Mar 2025) to 771.00 Cr., marking an increase of 110.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 10,825.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10,422.00 Cr. (Mar 2025) to 10,825.00 Cr., marking an increase of 403.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,697.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,745.00 Cr. (Mar 2025) to 1,697.00 Cr., marking a decrease of 48.00 Cr..
- For CWIP, as of Sep 2025, the value is 53.00 Cr.. The value appears strong and on an upward trend. It has increased from 42.00 Cr. (Mar 2025) to 53.00 Cr., marking an increase of 11.00 Cr..
- For Investments, as of Sep 2025, the value is 3,293.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,790.00 Cr. (Mar 2025) to 3,293.00 Cr., marking an increase of 503.00 Cr..
- For Other Assets, as of Sep 2025, the value is 5,783.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,845.00 Cr. (Mar 2025) to 5,783.00 Cr., marking a decrease of 62.00 Cr..
- For Total Assets, as of Sep 2025, the value is 10,825.00 Cr.. The value appears strong and on an upward trend. It has increased from 10,422.00 Cr. (Mar 2025) to 10,825.00 Cr., marking an increase of 403.00 Cr..
Notably, the Reserves (10,034.00 Cr.) exceed the Borrowings (4.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 185.00 | 150.00 | 385.00 | 619.00 | 529.00 | 701.00 | 950.00 | -4.00 | -4.00 | -3.00 | -3.00 | -4.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 62 | 62 | 95 | 103 | 107 | 90 | 83 | 71 | 89 | 87 | 103 | 101 |
| Inventory Days | 229 | 283 | 248 | 271 | 283 | 388 | 250 | 312 | 205 | 421 | 253 | 265 |
| Days Payable | 74 | 58 | 60 | 136 | 161 | 190 | 82 | 97 | 80 | 128 | 56 | 81 |
| Cash Conversion Cycle | 217 | 288 | 283 | 239 | 229 | 289 | 251 | 286 | 214 | 381 | 299 | 284 |
| Working Capital Days | 100 | 141 | 155 | 154 | 185 | 191 | 161 | 169 | 168 | 241 | 224 | 249 |
| ROCE % | 39% | 22% | 28% | 30% | 22% | 27% | 30% | 28% | 25% | 15% | 17% | 16% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid Cap Fund | 5,860,179 | 1.09 | 1009.12 | N/A | N/A | N/A |
| SBI Large & Midcap Fund | 3,170,000 | 1.46 | 545.87 | 2,000,000 | 2025-12-08 00:33:59 | 58.5% |
| Mirae Asset Large & Midcap Fund | 3,110,648 | 1.22 | 535.65 | 3,075,998 | 2026-01-25 03:15:35 | 1.13% |
| Nippon India Growth Mid Cap Fund | 2,800,000 | 1.14 | 482.16 | N/A | N/A | N/A |
| ICICI Prudential India Opportunities Fund | 2,767,517 | 1.37 | 476.57 | 2,532,645 | 2026-01-25 03:15:35 | 9.27% |
| Mirae Asset ELSS Tax Saver Fund | 2,283,927 | 1.45 | 393.29 | 2,250,770 | 2026-01-25 03:15:35 | 1.47% |
| Mirae Asset Large Cap Fund | 2,105,893 | 0.87 | 362.63 | 2,337,906 | 2025-12-08 00:33:59 | -9.92% |
| Nippon India Small Cap Fund | 1,780,371 | 0.45 | 306.58 | 1,696,933 | 2025-12-08 00:33:59 | 4.92% |
| Mirae Asset Midcap Fund | 1,676,184 | 1.57 | 288.64 | N/A | N/A | N/A |
| Nippon India Multi Cap Fund | 1,466,415 | 0.5 | 252.52 | 1,416,437 | 2025-12-08 00:33:59 | 3.53% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 42.40 | 46.90 | 47.44 | 73.81 | 63.07 |
| Diluted EPS (Rs.) | 42.40 | 46.90 | 47.43 | 73.81 | 62.99 |
| Cash EPS (Rs.) | 65.33 | 67.82 | 56.33 | 80.46 | 66.98 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 555.40 | 529.65 | 483.23 | 435.64 | 360.86 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 555.40 | 529.65 | 483.23 | 435.64 | 360.86 |
| Revenue From Operations / Share (Rs.) | 340.89 | 343.92 | 220.07 | 267.85 | 211.68 |
| PBDIT / Share (Rs.) | 89.98 | 91.27 | 76.82 | 105.54 | 87.84 |
| PBIT / Share (Rs.) | 67.05 | 70.35 | 67.91 | 98.83 | 81.80 |
| PBT / Share (Rs.) | 64.50 | 68.76 | 64.03 | 98.51 | 81.59 |
| Net Profit / Share (Rs.) | 42.40 | 46.90 | 47.42 | 73.75 | 60.94 |
| NP After MI And SOA / Share (Rs.) | 42.40 | 46.90 | 47.42 | 73.75 | 60.94 |
| PBDIT Margin (%) | 26.39 | 26.53 | 34.90 | 39.40 | 41.49 |
| PBIT Margin (%) | 19.66 | 20.45 | 30.85 | 36.89 | 38.64 |
| PBT Margin (%) | 18.92 | 19.99 | 29.09 | 36.77 | 38.54 |
| Net Profit Margin (%) | 12.43 | 13.63 | 21.54 | 27.53 | 28.79 |
| NP After MI And SOA Margin (%) | 12.43 | 13.63 | 21.54 | 27.53 | 28.79 |
| Return on Networth / Equity (%) | 7.63 | 8.85 | 9.81 | 16.92 | 16.88 |
| Return on Capital Employeed (%) | 11.43 | 12.50 | 13.89 | 22.39 | 22.36 |
| Return On Assets (%) | 6.22 | 7.24 | 8.89 | 15.46 | 15.34 |
| Long Term Debt / Equity (X) | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.02 | 0.03 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.51 | 0.58 | 0.43 | 0.61 | 0.65 |
| Current Ratio (X) | 4.33 | 4.04 | 9.46 | 10.05 | 10.00 |
| Quick Ratio (X) | 3.26 | 2.85 | 6.80 | 8.02 | 7.51 |
| Inventory Turnover Ratio (X) | 3.36 | 1.25 | 1.10 | 1.66 | 1.72 |
| Dividend Payout Ratio (NP) (%) | 47.17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 30.61 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 52.83 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 69.39 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 35.30 | 57.38 | 169.90 | 330.81 | 421.28 |
| Interest Coverage Ratio (Post Tax) (X) | 17.63 | 30.48 | 113.46 | 232.15 | 293.28 |
| Enterprise Value (Cr.) | 23946.09 | 28818.28 | 17126.99 | 50622.63 | 37532.51 |
| EV / Net Operating Revenue (X) | 4.26 | 5.09 | 4.73 | 11.50 | 10.84 |
| EV / EBITDA (X) | 16.15 | 19.17 | 13.54 | 29.19 | 26.12 |
| MarketCap / Net Operating Revenue (X) | 4.67 | 5.36 | 5.76 | 12.21 | 11.71 |
| Retention Ratios (%) | 52.82 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 2.87 | 3.48 | 2.63 | 7.50 | 6.87 |
| Price / Net Operating Revenue (X) | 4.67 | 5.36 | 5.76 | 12.21 | 11.71 |
| EarningsYield | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 |
After reviewing the key financial ratios for Gland Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 42.40. This value is within the healthy range. It has decreased from 46.90 (Mar 24) to 42.40, marking a decrease of 4.50.
- For Diluted EPS (Rs.), as of Mar 25, the value is 42.40. This value is within the healthy range. It has decreased from 46.90 (Mar 24) to 42.40, marking a decrease of 4.50.
- For Cash EPS (Rs.), as of Mar 25, the value is 65.33. This value is within the healthy range. It has decreased from 67.82 (Mar 24) to 65.33, marking a decrease of 2.49.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 555.40. It has increased from 529.65 (Mar 24) to 555.40, marking an increase of 25.75.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 555.40. It has increased from 529.65 (Mar 24) to 555.40, marking an increase of 25.75.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 340.89. It has decreased from 343.92 (Mar 24) to 340.89, marking a decrease of 3.03.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 89.98. This value is within the healthy range. It has decreased from 91.27 (Mar 24) to 89.98, marking a decrease of 1.29.
- For PBIT / Share (Rs.), as of Mar 25, the value is 67.05. This value is within the healthy range. It has decreased from 70.35 (Mar 24) to 67.05, marking a decrease of 3.30.
- For PBT / Share (Rs.), as of Mar 25, the value is 64.50. This value is within the healthy range. It has decreased from 68.76 (Mar 24) to 64.50, marking a decrease of 4.26.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 42.40. This value is within the healthy range. It has decreased from 46.90 (Mar 24) to 42.40, marking a decrease of 4.50.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 42.40. This value is within the healthy range. It has decreased from 46.90 (Mar 24) to 42.40, marking a decrease of 4.50.
- For PBDIT Margin (%), as of Mar 25, the value is 26.39. This value is within the healthy range. It has decreased from 26.53 (Mar 24) to 26.39, marking a decrease of 0.14.
- For PBIT Margin (%), as of Mar 25, the value is 19.66. This value is within the healthy range. It has decreased from 20.45 (Mar 24) to 19.66, marking a decrease of 0.79.
- For PBT Margin (%), as of Mar 25, the value is 18.92. This value is within the healthy range. It has decreased from 19.99 (Mar 24) to 18.92, marking a decrease of 1.07.
- For Net Profit Margin (%), as of Mar 25, the value is 12.43. This value exceeds the healthy maximum of 10. It has decreased from 13.63 (Mar 24) to 12.43, marking a decrease of 1.20.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.43. This value is within the healthy range. It has decreased from 13.63 (Mar 24) to 12.43, marking a decrease of 1.20.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.63. This value is below the healthy minimum of 15. It has decreased from 8.85 (Mar 24) to 7.63, marking a decrease of 1.22.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.43. This value is within the healthy range. It has decreased from 12.50 (Mar 24) to 11.43, marking a decrease of 1.07.
- For Return On Assets (%), as of Mar 25, the value is 6.22. This value is within the healthy range. It has decreased from 7.24 (Mar 24) to 6.22, marking a decrease of 1.02.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.51. It has decreased from 0.58 (Mar 24) to 0.51, marking a decrease of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 4.33. This value exceeds the healthy maximum of 3. It has increased from 4.04 (Mar 24) to 4.33, marking an increase of 0.29.
- For Quick Ratio (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 2. It has increased from 2.85 (Mar 24) to 3.26, marking an increase of 0.41.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.36. This value is below the healthy minimum of 4. It has increased from 1.25 (Mar 24) to 3.36, marking an increase of 2.11.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 47.17. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 47.17, marking an increase of 47.17.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 30.61. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 30.61, marking an increase of 30.61.
- For Earning Retention Ratio (%), as of Mar 25, the value is 52.83. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 52.83, marking an increase of 52.83.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 69.39. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 69.39, marking an increase of 69.39.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 35.30. This value is within the healthy range. It has decreased from 57.38 (Mar 24) to 35.30, marking a decrease of 22.08.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 17.63. This value is within the healthy range. It has decreased from 30.48 (Mar 24) to 17.63, marking a decrease of 12.85.
- For Enterprise Value (Cr.), as of Mar 25, the value is 23,946.09. It has decreased from 28,818.28 (Mar 24) to 23,946.09, marking a decrease of 4,872.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.26. This value exceeds the healthy maximum of 3. It has decreased from 5.09 (Mar 24) to 4.26, marking a decrease of 0.83.
- For EV / EBITDA (X), as of Mar 25, the value is 16.15. This value exceeds the healthy maximum of 15. It has decreased from 19.17 (Mar 24) to 16.15, marking a decrease of 3.02.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.67. This value exceeds the healthy maximum of 3. It has decreased from 5.36 (Mar 24) to 4.67, marking a decrease of 0.69.
- For Retention Ratios (%), as of Mar 25, the value is 52.82. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 52.82, marking an increase of 52.82.
- For Price / BV (X), as of Mar 25, the value is 2.87. This value is within the healthy range. It has decreased from 3.48 (Mar 24) to 2.87, marking a decrease of 0.61.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.67. This value exceeds the healthy maximum of 3. It has decreased from 5.36 (Mar 24) to 4.67, marking a decrease of 0.69.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gland Pharma Ltd:
- Net Profit Margin: 12.43%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.43% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.63% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 17.63
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.26
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 25.5 (Industry average Stock P/E: 46.53)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.43%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Sy.No. 143-148, 150 & 151, Hyderabad Telangana 500043 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Srinivas Sadu | Executive Chairman |
| Mr. Wenjie Zhang | Non Exe.Non Ind.Director |
| Mr. Wei Huang | Non Exe.Non Ind.Director |
| Dr. Jia Ai (Allen) Zhang | Non Exe.Non Ind.Director |
| Mr. Essaji Goolam Vahanvati | Independent Director |
| Mr. Udo Johannes Vetter | Independent Director |
| Mr. Satyanarayana Murthy Chavali | Independent Director |
| Ms. Naina Lal Kidwai | Independent Director |
FAQ
What is the intrinsic value of Gland Pharma Ltd?
Gland Pharma Ltd's intrinsic value (as of 01 February 2026) is ₹1443.14 which is 21.31% lower the current market price of ₹1,834.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹30,238 Cr. market cap, FY2025-2026 high/low of ₹2,131/1,200, reserves of ₹10,034 Cr, and liabilities of ₹10,825 Cr.
What is the Market Cap of Gland Pharma Ltd?
The Market Cap of Gland Pharma Ltd is 30,238 Cr..
What is the current Stock Price of Gland Pharma Ltd as on 01 February 2026?
The current stock price of Gland Pharma Ltd as on 01 February 2026 is ₹1,834.
What is the High / Low of Gland Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gland Pharma Ltd stocks is ₹2,131/1,200.
What is the Stock P/E of Gland Pharma Ltd?
The Stock P/E of Gland Pharma Ltd is 25.5.
What is the Book Value of Gland Pharma Ltd?
The Book Value of Gland Pharma Ltd is 610.
What is the Dividend Yield of Gland Pharma Ltd?
The Dividend Yield of Gland Pharma Ltd is 0.98 %.
What is the ROCE of Gland Pharma Ltd?
The ROCE of Gland Pharma Ltd is 15.8 %.
What is the ROE of Gland Pharma Ltd?
The ROE of Gland Pharma Ltd is 11.6 %.
What is the Face Value of Gland Pharma Ltd?
The Face Value of Gland Pharma Ltd is 1.00.